Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood

ConclusionGender-related differences in doxorubicin pharmacology may account for worse outcomes for male AYAs with chemosensitive cancers compared to females. These findings may reduce the AYA survival gap compared to other age groups.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research